Kernel Launches Observational Study Using Flow2 Neuroimaging Technology to Identify Biomarkers of Depression Treatment Response

LOS ANGELES–(BUSINESS WIRE)–Kernel, an innovator in non-invasive neuroimaging technology, announces the first patient has been measured in an observational study of depression treatments using Kernel’s revolutionary Flow2 neuroimaging technology. The initial launch sites include Kadima Neuropsychiatry Institute, Bespoke Treatment, and ATP Clinical Research. The study utilizes Flow2 to measure patients…
Click here to view original post